Product Center
Phase III clinical trial of freeze-dried human rabies vaccine (human diploid cell) officially launched
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-12-08
- Views:
(Summary description)Today, the kickoff meeting for the Phase III clinical trial of the freeze-dried human rabies vaccine (human diploid cell) independently developed by Ab&B Bio-Tech Co., Ltd. (referred to as "Ab&B Bio") was successfully held at the research site in Hubei. This marks a crucial step towards the successful launch of the core product.
Phase III clinical trial of freeze-dried human rabies vaccine (human diploid cell) officially launched
(Summary description)Today, the kickoff meeting for the Phase III clinical trial of the freeze-dried human rabies vaccine (human diploid cell) independently developed by Ab&B Bio-Tech Co., Ltd. (referred to as "Ab&B Bio") was successfully held at the research site in Hubei. This marks a crucial step towards the successful launch of the core product.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-12-08 09:05
- Views:
Today, the kickoff meeting for the Phase III clinical trial of the freeze-dried human rabies vaccine (human diploid cell) independently developed by Ab&B Bio-Tech Co., Ltd. (referred to as "Ab&B Bio") was successfully held at the research site in Hubei. This marks a crucial step towards the successful launch of the core product.
Rabies is an acute infectious disease caused by the rabies virus (RABV) that is shared by humans and animals. It is widely distributed geographically and occurs in over 150 countries and regions worldwide. Once humans and animals fall ill, almost 100% of them die, posing a huge threat to human life safety. The onset time of rabies and the site of virus invasion are related to the speed at which the virus moves to the central nervous system, usually 20-60 days or longer or shorter after infection. Rabies manifests as acute encephalomyelitis, clinically characterized by central nervous system damage such as fear of water, wind, and difficulty swallowing, followed by loss of respiratory and circulatory function and death.
At present, there is no effective treatment for rabies, and prevention is crucial, among which vaccination is the most effective prevention and control measure. The human diploid cell rabies vaccine (HDCV) has been used for over 40 years in Europe and North America, and its safety and efficacy have been fully validated. It is internationally recognized as the "gold standard" for rabies vaccines and is often used as a benchmark for newly developed vaccines. The freeze-dried human rabies vaccine (human diploid cell) involved in this study has completed phase I clinical trials, and the results show that whether administered to the 10-60 age group using the Essen procedure or the Zagreb procedure, the vaccine exhibits good safety.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
